Retrospective, multicentre, naturalistic study including 182 patients with various psychiatric disorders: 

• It is intended to evaluate the effectiveness of Neuropharmagen® in the selection of pharmacological treatment, with the measurement of improvement in the clinical picture on the Clinical Global Impression – Severity scale (CGI-S) for 12 weeks.
• Patients over 18 years of age with a CGI-S status of 3 at the time of enrollment in the study who had at least one treatment failure due to low efficacy and/or resistance, regardless of the patient’s psychiatric diagnosis or other concomitant conditions.